Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR-Cas9 Tools, Reagents to New England Biolabs

NEW YORK – ERS Genomics said on Tuesday that it has signed an agreement with New England Biolabs granting NEB the rights to sell CRISPR-Cas9 tools and reagents from the ERS CRISPR IP portfolio.

Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.

NEB sells recombinant and native enzymes for genomic research and plans to expand its product lines into new areas of research including genome editing. Under the terms of the deal, the company would have the right to provide researchers with gene editing reagents and workflows.

Financial terms of the agreement were not disclosed.

"New England Biolabs is a recognized world leader in the discovery and production of enzymes for molecular biology applications," ERS CEO Eric Rhodes said in a statement. "Adding CRISPR-Cas9 to the company's portfolio ensures it can continue to support its customers in the latest areas of technology advancement."

Other licensees of ERS Genomics' CRISPR-Cas9 technology include Bioneer, Lonza Pharma & Biotech, DefiniGen, and Thermo Fisher Scientific.




The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.